Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4B | O94953 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23947948 | 0.90 | KDM4A (0.33) | KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL26306218 | 0.88 | HCAR1 (0.33) | KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL26306183 | 0.85 | HCAR1 (0.34) | — | |
| SCHEMBL26306161 | 0.82 | EP300 (0.32) | — | |
| SCHEMBL23948303 | 0.81 | KCNH2 (0.38) | KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL23948451 | 0.81 | SCD (0.30) | SCD | |
| SCHEMBL23948296 | 0.78 | TDO2 (0.41) | ALDH1A1 | |
| SCHEMBL23948428 | 0.76 | EGLN1 (0.36) | — | |
| SCHEMBL23948442 | 0.76 | IRAK4 (0.33) | ALDH1A1 | |
| SCHEMBL23947915 | 0.75 | HCAR1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242536-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | PYRAMID BIOSCIENCES, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2021211882-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | PYRAMID BIOSCIENCES, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242536-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | LTK, FRK, LCK | KDM4A 3397/4885KDM4B 2999/4885KDM5C 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.